News

The United States Preventive Services Task Force (USPSTF) has issued 2021 guidelines for lung cancer screening. The last change made to these guidelines was in 2013. A screening test is...

The U.S. Food and Drug Administration (FDA) has approved Coselsa (trilaciclib) to protect bone marrow from damage caused by chemotherapy. Coselsa is approved for use in adults receiving certain types...

The American Cancer Society (ACS) has released its 2021 report on cancer, called Cancer Facts and Figures 2021. The data in this report is 2 to 4 years behind the...

The U.S. Food and Drug Administration (FDA) has granted a new indication (use) for Tagrisso® (osimertinib). The latest indication is for adjuvant therapy after tumor resection (removal) in people with...

Editor’s Note: This article was first published on August 20, 2020. Further developments in what we know about the coronavirus are continuously emerging. Learn more in Self-Care in Uncertain Times...

Even after months of navigating life in the COVID-19 era, keeping up with new information and news can be overwhelming. Below are some of the latest developments surrounding COVID-19 for...

The United States Food and Drug Administration (US FDA) has approved Zepzelca for the treatment of small cell lung cancer (SCLC). Zepzelca (lurbinectedin) is specifically used for adults whose cancer...

Many of us are overwhelmed by the amount of information available on COVID-19. Keeping up with all of the news can be challenging. Here are some of the top developments...

On May 22, 2020, the U.S. Food and Drug Administration (FDA) approved AlunbrigTM (brigatinib) for adults with ALK+ metastatic non-small cell lung cancer (NSCLC) who had not previously received an...

The United States Food and Drug Administration (US FDA) has expanded the use of Tecentriq for non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) has been approved in the past for...

The United States Food and Drug Administration (US FDA) has approved the use of Opdivo (nivolumab) and Yervoy (ipilimumab) together for non-small cell lung cancer (NSCLC). Opdivo (nivolumab) and Yervoy...

Lung cancer is the second most common cancer in both men and women accounting for 13 percent of all new cancers. Approximately 15 percent of all lung cancers are small...

Our world is still changing every day because of COVID-19. Keeping up with all of the news can be challenging. Here are some of the top COVID-19 updates for people...

It is common to feel overwhelmed about COVID-19: so much information changing day-to-day. Here are some of the important COVID-19 stories that may be applicable to people living with one...

This article was written on March 31, 2020. Further developments in what we know about the coronavirus are continuously emerging. Learn more in Self-Care in Uncertain Times. The spread of...

The United States Food and Drug Administration (US FDA) has approved the drug Imfinzi (durvalumab) for small-cell lung cancer. Imfinzi is specifically for people with small-cell lung cancer that has...

The 2020 Fatigue and Health survey has now closed. Thank you for your interest! We are excited to share the results with you soon.Exhaustion, tiredness, weariness... fatigue. We know chronic...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small...

On March 19, the U.S. Food and Drug Administration (FDA) approved the testing of two drugs, chloroquine (hydroxychloroquine) and remdesivir, to treat people with COVID-19. The drugs have been given...

In its Lung Cancer Scorecard, LUNGevity Foundation grades each state on its access to care and lung cancer statistics. Based on their analysis, over half of the states receive a...